Cargando…
Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer
Insurance coverage policies are a major determinant of patient access to genomic tests. The objective of this study was to examine differences in coverage policies for guideline-recommended pharmacogenomic tests that inform cancer treatment. We analyzed coverage policies from eight Medicare contract...
Autores principales: | Lu, Christine Y., Loomer, Stephanie, Ceccarelli, Rachel, Mazor, Kathleen M., Sabin, James, Clayton, Ellen Wright, Ginsburg, Geoffrey S., Wu, Ann Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023380/ https://www.ncbi.nlm.nih.gov/pubmed/29772692 http://dx.doi.org/10.3390/jpm8020019 |
Ejemplares similares
-
The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies
por: Wu, Ann Chen, et al.
Publicado: (2018) -
Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients
por: Wu, Ann Chen, et al.
Publicado: (2017) -
Insurance Coverage Policies for Personalized Medicine
por: Hresko, Andrew, et al.
Publicado: (2012) -
Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021) -
Public Health Policy in Support of Insurance Coverage for Smoking Cessation Treatments
por: Schwartz, Robert, et al.
Publicado: (2017)